Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Holoclar for limbal stem cell deficiency due to ocular burns
NL-OMON50240Phase 4Active, not recruiting
- Sponsor
- Holostem
- Start
- Oct 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label trial of ex vivo reconstructed autologous human corneal epithelium containing stem cells in limbal stem cell deficiency (LSCD) (2 arms), sponsored by Holostem. Primary endpoint: Transplantation success at approximately 12 months after first Holoclar treatment. Started Oct 2016; status: active, not recruiting.
02
Drugs
ex vivo reconstructed autologous human corneal epithelium containing stem cells
03
Conditions
limbal stem cell deficiency (LSCD)
Beyond the preview
Go deeper on NL-OMON50240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50240.